Thread by @HansrajCapital

#Syngene FY22 Annual Report is out.

Here are some key takeaways from it👇

🧵🧵🧵🧵🧵

𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀 𝗮𝗿𝗲 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝗲𝗱 𝗯𝘆 𝗳𝗼𝘂𝗿 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗱𝗶𝘃𝗶𝘀𝗶𝗼𝗻𝘀

1⃣ 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀

2⃣ 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀

Global CRO and CDMO Industry Growth Outlook and their driving factors

1. Growth in pharmaceutical R&D investment

2. Increasing R&D costs and complexity

3. Increasing use of disruptive technologies

4. Growing innovation by small/virtual biotech companies

5. Manufacturing outsourcing by biopharmaceutical companies

6. Pandemic-induced demand for R&D services

𝗙𝗬𝟮𝟮 𝗣𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲 𝗮𝗻𝗱 𝗙𝘂𝘁𝘂𝗿𝗲 𝗢𝘂𝘁𝗹𝗼𝗼𝗸

𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗣𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲

Beyond the numbers, there are numerous successful case studies which uniquely positioned Syngene.

During the year, Discovery Chemistry scientists were listed as authors in four publications and as inventors on eight patent applications, reaffirming their wider contribution to science and delivering unique value for clients.

During the year, Discovery Biology scientists were listed as authors in five publications and four posters were presented in events.

NDA Include Syngene as API Supplier

Company has one subsidiary for its US operations

Management Numeration growth for FY21 and FY22